GlassScriptPhysician profile
Travis W Hamblin
NPI 1427344415
$611.21
in general payments reported to CMS, 2019-2025
10 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.54 · 2020: $54.77 · 2021: $44.18 · 2022: $121 · 2023: $122 · 2024: $63.58 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $83.78 | 2020-2025 | |
| Galderma Laboratories, L.P. | $47.74 | 2020-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.52 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $36.77 | 2022-2025 | |
| Hill Dermaceuticals, INC. | $36.29 | 2025 | Tolak |
| Integra Lifesciences Corporation | $32.97 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Allergan, INC. | $21.75 | 2021 | |
| Incyte Corporation | $18.12 | 2023 | Opzelura |
| Dermavant Sciences, INC. | $15.08 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Hamblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.